 NEW YORK, Dec. 7, 2020 PRNewswire -- Relmada Therapeutics, Inc. Nasdaq: RLMD, a late-stage biotechnology company addressing diseases of the central nervous system CNS, today announced that the first patient has been enrolled in the first Phase 3 clinical trial RELIANCE I for the... 